Cue Biopharma, Inc. (CUE) Financial Statements (2024 and earlier)

Company Profile

Business Address 40 GUEST STREET
BOSTON, MA 02135
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments54,69157,88966,19976,28959,18366,126
Cash and cash equivalents54,69152,90156,32151,61429,72666,126
Short-term investments  4,9889,87824,67529,457 
Receivables1,6611,13519657796736
Other undisclosed current assets1,1651,9112,3608411,7212,142
Total current assets:57,51760,93568,75577,18761,70069,004
Noncurrent Assets
Operating lease, right-of-use asset7,0607,7868,5009,2039,5619,899
Property, plant and equipment1,0641,1921,3251,4991,6421,765
Deposits noncurrent assets2,9772,9772,9773,1163,1163,797
Restricted cash and investments150150 150150150
Other noncurrent assets120123125128131134
Total noncurrent assets:11,37112,22812,92714,09614,60015,745
TOTAL ASSETS:68,88873,16381,68291,28376,30084,749
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,6076,4324,9946,2855,9245,127
Accounts payable2,4802,3562,1512,7312,0451,568
Accrued liabilities5,1274,0762,8433,5543,8793,559
Debt4,0004,0003,0002,0741,037 
Other undisclosed current liabilities5,6005,8755,8163,1893,2613,196
Total current liabilities:17,20716,30713,81011,54910,2228,323
Noncurrent Liabilities
Long-term debt and lease obligation5,1606,1187,0778,03515,31416,670
Long-term debt, excluding current maturities5,1606,1187,0778,0358,9939,913
Liabilities, other than long-term debt3,8554,5985,3336,018  
Operating lease, liability3,8554,5985,3336,0186,3216,757
Other undisclosed noncurrent liabilities  136445 (6,321)(6,757)
Total noncurrent liabilities:9,01510,85212,85514,05215,31416,670
Total liabilities:26,22227,15926,66525,60125,53624,993
Equity
Equity, attributable to parent42,66646,00455,01765,68350,76459,756
Common stock454443433535
Additional paid in capital330,376322,715318,578316,192286,685284,630
Accumulated other comprehensive loss  (5)(39)(96)(92) 
Accumulated deficit(287,755)(276,750)(263,565)(250,457)(235,864)(224,909)
Total equity:42,66646,00455,01765,68350,76459,756
TOTAL LIABILITIES AND EQUITY:68,88873,16381,68291,28376,30084,749

Income Statement (P&L) ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Revenues2,1001,3821871516826
Gross profit:2,1001,3821871516826
Operating expenses(13,519)(14,899)(13,567)(15,017)(11,099)(13,116)
Operating loss:(11,419)(13,517)(13,380)(14,866)(11,031)(13,090)
Nonoperating income (expense)41433227127376(118)
Interest and debt expense(254)(350)(330)(271)(124)(206)
Loss from continuing operations before equity method investments, income taxes:(11,259)(13,535)(13,439)(14,863)(11,079)(13,414)
Other undisclosed income from continuing operations before income taxes    626  
Loss from continuing operations:(11,259)(13,535)(13,439)(14,237)(11,079)(13,414)
Loss before gain (loss) on sale of properties:(11,079)(13,414)
Other undisclosed net income (loss)  330(355)  
Net loss:(11,259)(13,535)(13,109)(14,592)(11,079)(13,414)
Other undisclosed net income attributable to parent 254350  124206
Net loss available to common stockholders, diluted:(11,005)(13,185)(13,109)(14,592)(10,955)(13,208)

Comprehensive Income ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Net loss:(11,259)(13,535)(13,109)(14,592)(11,079)(13,414)
Other comprehensive income (loss) 53457(4)(92) 
Comprehensive loss:(11,254)(13,501)(13,052)(14,596)(11,171)(13,414)
Other undisclosed comprehensive income, net of tax, attributable to parent 254350  124206
Comprehensive loss, net of tax, attributable to parent:(11,000)(13,151)(13,052)(14,596)(11,047)(13,208)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: